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ackground: House dust mite (HDM) allergy is associated with persistent allergic rhinitis (AR) and allergic
sthma.
bjective: To investigate the efﬁcacy and safety of a SQ HDM sublingually administered immunotherapy
blet (ALK, Hørsholm, Denmark) in adults and adolescents with HDM respiratory allergic disease and report
e AR results.
Methods: Six hundred four subjects at least 14 years old with HDM AR and mild to moderate HDM allergic
asthmawere randomized 1:1:1:1 to double-blinded daily treatment with 1, 3, 6 SQ-HDM or placebo. End-of-
treatment rhinoconjunctivitis symptoms and medication score were predeﬁned extrapulmonary end points.
A subgroup analysis was conducted post hoc in subjects with a total combined rhinitis score (TCRS) > 0 (ie,
with AR symptoms and/or AR medication use during the 4-week baseline period). The subgroup was
comprised of 498 subjects (82%).
Results: In the subgroup, the absolute difference in end-of-treatment TCRS between 6 SQ-HDM and placebo was
0.78 (95% conﬁdence interval 1.47 to0.07, relative difference 28.8%, P¼ .0357). Furthermore, a signiﬁcant dif-
ferencewas found for the total scoreof theRhinitisQualityofLifeQuestionnairewithStandardizedActivitiesRQLQ(S)
and for the individualdomains:activities, sleep,non-noseandnon-eyesymptoms,andnasal symptoms. For theTCRS
and Rhinitis Quality of Life Questionnaire score, a dose response was seen, with numerically lower, nonsigniﬁcant
differences for 1 and 3 SQ-HDM. The predeﬁned analysis for the entire trial population showed no statistically sig-
niﬁcant difference between the placebo and actively treated groups. No safety concerns were observed.
Conclusion: Efﬁcacy in mild to severe AR of 6 SQ-HDM compared with placebo was demonstrated by
statistically signiﬁcant improvements in TCRS and Rhinitis Quality of Life Questionnaire score in subjects with
AR present at baseline. The treatment was well tolerated.
Trial Registration: EudraCT, no 2006-001795-20; ClinicalTrials.gov, identiﬁer NCT00389363.
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Patients with house dust mite (HDM) respiratory allergic disease
can have symptoms from both the upper (allergic rhinitis [AR]) and
lower (allergic asthma [AA]) respiratory tract. Nearly all patientswith
AA and HDM sensitization have AR, and approximately half the pa-
tients with AR and HDM sensitization have asthma.1 Allergy immu-
notherapy targets the underlying allergic disease and thus could have
beneﬁcial effectsonclinical symptomsmanifestingasAA,ARorboth.2lsevier Inc. This is an open access article under the CC BY-NC-ND license (http://
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immunotherapy (SLIT) tablet (ALK, Hørsholm, Denmark) in mild to
moderate HDM AA has recently been described.3 This randomized,
double-blinded, placebo-controlled phase II/III trial conﬁrmed ef-
ﬁcacy in mild to moderate AA of 6 SQ-HDM compared with placebo
and the treatment could reduce the inhaled corticosteroid (ICS)
dose required to maintain asthma control. The primary analysis
revealed a mean difference between 6 SQ-HDM and placebo in the
reduction in daily ICS dose of 81 mg (P ¼ .004). Relative mean and
median reductions were 42% and 50% for 6 SQ-HDM and 15% and
25% for placebo.3
Allergic rhinoconjunctivitis was assessed as a secondary
objective in this trial, and eligibility required a history of HDM AR
and HDM AA and a positive test of sensitization. A proportion of
the trial subjects reported no rhinitis symptoms and no use of
pharmacotherapy for AR during the entire 4-week baseline
period. The remaining subjects (82% of entire trial population) had
a non-zero total combined rhinitis score (TCRS; ie, sum of AR daily
symptoms score and daily AR medication score averaged over 4-
week baseline period). The effect of the SQ HDM SLIT-tablet in
this subgroup of subjects with symptoms from HDM AR at any
time during the 4-week baseline period before randomizationwas
investigated post hoc.
Quality of life in patients with HDM allergy may be impaired by
a high level of nasal symptoms associated with impaired sleep
caused by symptoms such as a blocked nose,4,5 whereas eye
symptoms less frequently affect sleep and quality of life in patients
with HDM allergy.6,7 Hence, nasal symptoms seem to be the
predominant and clinically most relevant extrapulmonary mani-
festation of HDM allergy. For this reason, the subgroup analysis is
focused on AR.
The trial was sponsored by ALK.Methods
The methods described herein are pertinent to the AR results. A
detailed description of the trial and the results related to asthma
have been published.3Trial Design
This was a multisite, multiple-dose, randomized, double-
blinded, parallel-group, placebo-controlled trial performed at 81
sites in Denmark, Germany, Italy, Spain, United Kingdom, Sweden,
France, and Poland. The trial design is presented in Figure 1.
Subjects were randomized (1:1:1:1) to double-blinded treat-
ment with 1, 3, or 6 SQ-HDM or placebo as 1 daily tablet admin-
istered sublingually. Subjects received intervention treatment for
approximately 12 months.Figure 1. Trial design depicts the 4-week periods when assessments of allergic
rhinitis symptoms and medication use are equivalent to the inhaled corticosteroid
stable periods used for assessing the allergic asthma end point.3Trial Population
The trial population was comprised of subjects at least 14 years
of age with controlled asthma (as deﬁned by the Asthma Control
Questionnaire8), mild to moderate HDM AA requiring ICS use
(100e800 mg/day of budesonide or equivalent), a clinical history
of HDM AR, a positive skin prick test (wheal diameter 3 mm), and
speciﬁc IgE (0.70 kU/L) to Dermatophagoides pteronyssinus and/or
Dermatophagoides farinae. The population was characterized by
assessing demographic parameters and disease-speciﬁc parame-
ters, such as sensitization pattern, disease severity, and comor-
bidities. The subgroup consisted of 82% of the entire trial
population who reported AR symptoms and/or medication use,
demonstrated as a TCRS > 0, during the 4-week baseline period.
Intervention Medication
The tablets (active and placebo) were manufactured and pro-
vided by the sponsor and were oral lyophilisates containing stan-
dardized extracts of D pteronyssinus and D farinae in a 1:1 ratio or a
placebo that was similar in appearance, smell, and taste. Three
active strengths were investigated: 1, 3, and 6 SQ-HDM. In previous
publications (abstracts and phase I publication9), the units were
designated in development units. One development unit corre-
sponds to 1 SQ-HDM. The sponsor provided ICS and rescue medi-
cation to relieve asthma and rhinoconjunctivitis symptoms.
Randomization
Randomization was performed according to the sponsor-
generated allocation schedule by a trial-independent statistician.3
End Points and Assessments
The prespeciﬁed extrapulmonary end points for the entire trial
population comprised rhinoconjunctivitis symptoms and medica-
tion scores and Rhinitis Quality of Life Questionnaire with Stan-
dardized Activities (RQLQ[S]) scores.10 The end points analyzed in
the post hoc analysis of the subgroup with AR at baseline
comprised the TCRS, AR symptoms, AR medication, the RQLQ(S),
and the individual RQLQ(S) domains. The composite end point,
TCRS, was the sum of the daily AR symptoms and daily AR medi-
cation score averaged over the 4-week end-of-trial efﬁcacy
assessment period. The range of the score was 0 to 24, as detailed
below.
Symptoms during the past 24 hours were evaluated by the
subjects in an electronic diary by scoring 4 nose symptoms (runny
nose, sneezing, itchy nose, and blocked nose) and 2 eye symptoms
(watery eyes and gritty feeling/red/itchy eyes) on a scale of 0 to 3
(no symptoms, mild symptoms, moderate symptoms, and severe
symptoms). For the subgroup analysis, omission of eye symptoms
led to a maximum daily AR symptom score of 12.
Additional pharmacotherapy against allergic symptoms was
standardized and taken in the form of desloratadine tablets at a
maximum of 5 mg daily, 32 mg of budesonide nasal spray at a
maximum of 2 puffs per nostril daily, and 5mg of prednisone in the
event of exacerbations. Subjects were instructed to take these
medications only when needed for control of their symptoms. Once
symptoms were alleviated, the subject had to stop taking phar-
macotherapy. The use of pharmacotherapy was recorded in the
daily diary and the medication scoring scale was not disclosed to
the trial subjects. Oral prednisone was used by only a few subjects
and it had no inﬂuence on the AR end point and thus was omitted
from the assessment of the AR medication score. Desloratadine had
a score of 4 (for 5 mg) and budesonide had a score of 8 (2 per puff),
leading to a maximum daily AR medication score of 12.
The RQLQ(S) is comprised of 28 items in 7 domains, with each
scored on a 7-point scale (0, no impairment; 6, maximum
H. Mosbech et al. / Ann Allergy Asthma Immunol 114 (2015) 134e140136impairment). Subjects were to respond to each item after recalling
their experience during the past week. The 7 domains were activ-
ities, sleep, non-nose and non-eye symptoms, practical problems,
nasal symptoms, eye symptoms, and emotional.10 Overall scores
and domain scores were calculated for each subject at randomi-
zation/initiation of treatment (visit 4, baseline) and at the end-
of-trial visit (visit 12).
Symptoms, medication use, and RQLQ(S) were recorded daily by
subjects in an electronic diary during 4 weeks prior to randomi-
zation (baseline) and again after 1 year of treatment during the
efﬁcacy assessment, which took place over a period of 4 weeks
before the trial ended (Fig 1). The 4 weeks before randomization
(baseline period) and the 4 weeks at the end of treatment (efﬁcacy
assessment period) are equivalent to the ICS stable periods for the
assessment of asthma end points.3
Statistical Methodology
The efﬁcacy end point of the post hoc subgroup analysis was the
average TCRS during the efﬁcacy evaluation period. The end point
was analyzed using a linear mixed-effects model based on non-
missing observations of the population (subgroup with TCRS
>0 during baseline). The square root of the average TCRS was the
response variable, treatmentwas a ﬁxed class effect, the square root
of the average TCRS during baseline was a regression variable, and
country was a random class variable. The different residual error for
each treatment group was speciﬁed in the linear mixed-effects
model. The linear mixed-effects model was estimated using the
method of restricted maximum likelihood. Denominator degrees of
freedomwere calculated using the Kenward-Roger approximation.
Parameter estimates, back-transformed adjusted means, and
differences in back-transformed adjusted means were calculated
together with the SE. The difference in the back-transformed
adjusted means was calculated together with the associated
P value and 95% conﬁdence intervals.
The RQLQ(S) overall and domain scores were analyzed at the
end of the trial similarly to the primary end point,3 with a linear
mixedmodel including treatment group and baseline value as ﬁxed
effects and center as random effect, as described in the eMethods. A
description of the statistics for the predeﬁned extrapulmonary
analyses for the entire trial population is available in the eMethods.
Ethics
The trial is identiﬁed by EudraCT number 2006-001795-20 and
clinicaltrials.gov identiﬁer NCT00389363. The trial was designed,
approved, consented to, and conducted according to the principles
of Good Clinical Practice by the International Conference on
Harmonization of Technical Requirement for Registration of
Pharmaceuticals for Human Use.11 This included the collection of
written informed consent from all trial subjects before the initia-
tion of any trial-related procedures.Table 1
Subject disposition in subgroup with TCRS > 0 during baselinea
Placebo, n (%) 1 SQ-HDM, n (%) 3 SQ-
Randomized 107 (100) 117 (100) 131 (1
Withdrawn 69 (12) 11 (9) 20 (1
Withdrawal of consent 2 (2) 2 (2) 6 (5
Pregnancy 2 (2) 1 (<1) 2 (2
Lost to follow-up 3 (3) 1 (<1) 1 (<
Noncompliance 1 (<1) 3 (3) 2 (2
Adverse event 1 (<1) 2 (2) 7 (5
Other 2 (2) 2 (2) 2 (2
Completed 96 (90) 77 (66) 111 (8
Abbreviation: TCRS, total combined rhinitis score.
aAll randomized subjects were treated with the investigational medicinal product.Results
Trial Population
The entire trial population consisted of 604 randomized subjects
described in the primary publication.3 Of the entire trial popula-
tion, 489 randomized subjects (82%) had a TCRS > 0 during base-
line. Eight-nine percent of this subgroup completed the trial, evenly
distributed across treatment groups. The rate of adverse event (AE)
discontinuations was numerically slightly higher for 3 SQ-HDM
than for the other treatment groups, which also was the case for
the entire trial population.3
The subject disposition for this subgroup with a TCRS> 0 during
baseline is presented in Table 1.
Half the subjects were male, 98% were white, baseline body
measurements were within normal ranges, 83% were poly-
sensitized, and 6% were adolescents. Demographic and baseline
characteristics are presented in Figure 2.Efﬁcacy in Rhinitis
The efﬁcacy data representing the subgroup with a TCRS >
0 during baseline are presented in Figure 3, depicted as
dose-response curves. Values for medians and rawmeans are listed
in the panel section of Figure 3.
The statistical analysis of TCRS is presented in Table 2 in addition
to the analysis of the overall RQLQ(S) results for the subgroup.
A dose response was observed for the TCRS, with the most
pronounced effect in the 2 highest dose groups, and with the
difference from placebo being statistically signiﬁcant only for 6
SQ-HDM. For RQLQ(S), the difference between 6 SQ-HDM and
placebo also was statistically signiﬁcant, whereas the lower dose
groups yielded numerically smaller and nonsigniﬁcant effects.
For the individual components of the TCRS, the mean values of
symptoms score during baseline and at the end of treatment were
1.56 and 1.24 for 1 SQ-HDM, 1.75 and 1.14 for 3 SQ DHM, 1.54 and
1.10 for 6 SQ-HDM, and 1.69 and 1.49 for placebo. The mean values
for medication scores were 2.80 and 2.11 for 1 SQ-HDM, 3.27 and
2.22 for 3 SQ DHM, 2.92 and 2.14 for 6 SQ-HDM, and 2.89 and 2.61
for placebo.
The adjustedmean values at the end of treatment for 6 SQ-HDM
and placebo for the individual components of the TCRS (Fig 4)
showed that all individual scores were numerically lower for 6
SQ-HDM than for placebo, with statistically signiﬁcant differences
between the 2 groups for 3 of the 4 individual nose symptom
domains (runny nose, P ¼ .0086; blocked nose, P ¼ .0176; sneezing,
P ¼ .0254; itchy nose, P ¼ .0975). In addition to the RQLQ(S), the
individual domains of the RQLQ(S) were analyzed. The results are
shown in Figure 4 and showed statistically signiﬁcant differences
between 6 SQ-HDM and placebo for activities (P ¼ .0463), sleep
(P ¼ .0002), non-nose and non-eye symptoms (P ¼ .0062), and
nasal symptoms (P ¼ .0371).HDM, n (%) 6 SQ-HDM, n (%) Active all, n (%) Overall, n (%)
00) 134 (100) 382 (100) 489 (100)
5) 14 (10) 45 (12) 56 (11)
) 2 (1) 10 (3) 12 (2)
) 3 (<1) 5 (1)
1) 3 (2) 5 (1) 8 (2)
) 4 (3) 9 (2) 10 (2)
) 4 (3) 13 (3) 14 (3)
) 1 (<1) 5 (1) 7 (1)
5) 120 (90) 337 (88) 433 (89)
Figure 2. Demographic and baseline characteristics of subgroup with a TCRS> 0 during baseline. Age and HDM allergic rhinitis history were assessed at screening. Additional
sensitizations were any sensitizations apart from Dermatophagoides pteronyssinus and/or Dermatophagoides farinae, as assessed by skin prick testing at screening. Additional
indoor refers to at least 1 other indoor allergen (animal hair and dander, molds). Additional outdoor only refers to no other indoor allergens but at least 1 outdoor allergen. HDM,
house dust mite; TCRS, total combined rhinitis score.
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entire trial population (ie, including subjects with previous AR, but
no AR symptoms or medication during the baseline period) did not
show a statistically signiﬁcant difference between active treatment
and placebo; results and conclusions for this are available in the
eMethods.
A signiﬁcantly larger proportion of subjects with a TCRS ¼ 0
during baseline used a daily ICS dose > 400 mg budesonide at
baseline comparedwith subjects using a daily dose of ICS 400 mg atFigure 3. Empirical cumulative distribution of the change in TCRS from baseline to end of
means, and SDs for individual treatment groups. TCRS, total combined rhinitis score.baseline (23% and 16%, respectively). This difference was statistically
signiﬁcant (P ¼ .0301; see eMethods).Safety
The AEs are reported as Medical Dictionary for Regulatory
Activities preferred terms. This section concerns only AEs occurring
after randomization in the subgroup with a baseline TCRS > 0. The
data are presented in Table 3. Overall, the reporting pattern wastreatment for all treatment and placebo groups. The panel section lists medians, raw
Table 2
Statistical analyses of TCRS and RQLQ(S) in the subgroup with a TCRS higher than




Absolute (95% CI) Relative, % P value
TCRS
6 SQ-HDM 117 1.93 0.78 (1.52 to 0.04) 28.8 .036
3 SQ-HDM 112 2.01 0.70 (1.45 to 0.04) 26.0 .063
1 SQ-HDM 106 2.24 0.47 (1.24 to 0.30) 17.4 .23
Placebo 95 2.71
RQLQ(S)
6 SQ-HDM 119 0.80 0.24 (0.43 to 0.05) .012
3 SQ-HDM 112 0.89 0.15 (0.34 to 0.04) .11
1 SQ-HDM 104 0.89 0.15 (0.35 to 0.04) .13
Placebo 96 1.04
Abbreviations: CI, conﬁdence interval; RQLQ(S), Rhinitis Quality of Life Question-
naire with Standardized Activities; TCRS, total combined rhinitis score.
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than for 3 and 6 SQ-HDM. Themost frequent AEswere oral pruritus,
upper respiratory tract infections, and asthma, with upper respi-
ratory tract infections being reported with similar frequency in the
active treatment and placebo groups and oral pruritus and asthma
reportedmore frequently in the active treatment groups than in the
placebo group. All these reactions were mild or moderate in in-
tensity. For most subjects, the occurrence of local allergic reactions
after tablet administration abated within weeks to a few months.
For all 4 treatment groups, most asthma exacerbations that were
observed during the trial occurred during the ICS adjustment pe-
riods. Twenty-nine severe AEs were reported, with the highest rate
observed for 3 SQ-HDM. Two serious AEs were assessed by the
authors and the sponsor as related to the intervention: a case of
dizziness in the 3 SQ-HDMgroup and a case of migraine in the 1 SQ-
HDM group. Four severe AEs were assessed as related to the
treatment, and 2 of these were serious AE and were described
earlier. The remaining 2 cases were pruritus and facial edema. The
subject with pruritus developed symptoms 23 days after the ﬁrst
intake of the intervention medication. The subject received oral
antihistamines and the symptoms resolved after 9 days. There were
no changes to the intervention medication. The subject with facial
edema developed symptoms 65 days after the ﬁrst intake of the
intervention medication. The symptoms resolved within 1 day, and
the subject did not receive any treatment. The subject discontinued
the trial after this event. In total, 14 subjects (3%) discontinued the
trial prematurely because of an AE, with the highest rates observed
for 3 and 6 SQ-HDM (5% and 3%, respectively). No systemic allergic
reactions were reported, and no subjects required treatment withFigure 4. End-of-treatment scores for individual components of the total combined rhinit
and the 6 SQ-HDM group (orange) for the subgroup of subjects with TCRS > during baseli
designate statistically signiﬁcant differences between placebo and 6 SQ-HDM. RQLQ, Rhiepinephrine. The safety results for this subpopulation are overall
comparable to the safety results for the entire trial population.3Discussion
A treatment effect of 0.78 (95% conﬁdence interval 1.47
to 0.07) in TCRS was found for 6 SQ-HDM compared with placebo,
with the relative difference being 28.8%. The results are comparable
to what was found in a recently reported trial, although the scoring
scales differ between the 2 trials, preventing direct comparisons.
That trial assessed the efﬁcacy and safety of 2 doses of a different
HDM SLIT-tablet over 1 year in 509 subjects withmoderate to severe
HDM-induced AR.12 After 1 year of treatment, the 2 active doses
signiﬁcantly improved the primary end point of Average Adjusted
Symptom Score (a total symptom score adjusted for rescue medi-
cation use) by 17.9% and 20.2%, respectively, comparedwith placebo.
In contrast to the present study, there did not appear to be a signif-
icant dose-dependent effect for efﬁcacy.12 Taken together, these 2
trialswith different products support theHDMSLIT-tablet concept in
AR.
SLIT-tablet therapy has also has been shown to be effective in
pollen allergy-related symptoms.13e19 A direct comparison of HDM
SLIT-tablet with pollen SLIT-tablet trials is made difﬁcult by the fact
that symptom and medication scoring scales differ between trials,
especially because conjunctivitis symptoms are more prominent in
pollen allergy. However, overall, the measured relative treatment
effect in the present trial is within range of what has been seen in
pollen SLIT-tablet trials.13e19 The present results suggest a dose-
response trend, with the highest and only statistically signiﬁcant
effect compared with placebo observed for 6 SQ-HDM. This could be
a power issue, because this is a subgroup analysis and the trial was
not powered for analysis of AR but for an analysis of ICS reduction.
However, the results most likely imply that 1 and 3 SQ-HDM are
below the effective dose range for most patients. This is in accord
with the results for the asthma end points.3
In the post hoc analysis, the clinical effect of 6 SQ-HDM was
supported by a statistically signiﬁcant improvement of quality of life
as assessed with the RQLQ(S) instrument. In particular, nasal symp-
toms and sleep improved, and, interestingly, the difference in scores
was largest for blocked nose of the 4 individual nasal symptom
components of the TCRS. The literature suggests a link between AR,
impaired sleep, and decreased quality of life. Pathophysiologic
mechanisms can be ascribed to increased exposure to mite allergen
when in bed, circadian ﬂuctuations, and/or nighttime decreases in
cortisol levels that affect inﬂammatory cytokines and other media-
tors.20e22 Sleep disruption is frequent in patients with AR4,5,23 and is
believed to be strongly associated to nasal congestion,4,24,25 leadingis score (nasal symptoms andmedication) and RQLQ(S) in the placebo group (yellow)
ne. The scores are shown as adjusted means with 95% conﬁdence intervals. Asterisks
nitis Quality of Life Questionnaire with Standardized Activities.
Table 3
Summary of adverse events occurring after ﬁrst tablet intake in subgroup with TCRS > during baselinea
Placebo (n ¼ 107) 1 SQ-HDM (n ¼ 117) 3 SQ-HDM (n ¼ 131) 6 SQ-HDM (n ¼ 134) Active all (n ¼ 382) Overall (n ¼ 489)
n (%) E n (%) E n (%) E n (%) E n (%) E n (%) E
All AEs 61 (57) 152 64 (55) 177 88 (67) 299 88 (66) 297 240 (63) 775 301 (62) 925
Causality
Probable 7 (7) 10 20 (17) 37 40 (31) 83 43 (32) 89 103 (26) 254 110 (22) 219
Possible 12 (11) 18 8 (7) 11 21 (16) 27 16 (12) 32 45 (11) 80 57 (12) 88
Unlikely 56 (52) 124 53 (45) 129 69 (53) 189 69 (51) 176 191 (50) 494 247 (51) 618
Severity
Mild 50 (47) 93 50 (43) 104 69 (53) 201 72 (54) 189 191 (50) 494 241 (49) 587
Moderate 29 (27) 53 32 (27) 66 43 (33) 86 44 (33) 104 119 (31) 256 148 (30) 309
Severe 4 (4) 6 5 (4) 7 8 (6) 12 3 (2) 4 16 (4) 23 20 (4) 29
Seriousness
Not serious 60 (56) 146 63 (54) 171 87 (66) 296 87 (65) 290 237 (62) 757 297 (61) 905
Serious 3 (3) 4 5 (4) 6 3 (2) 3 6 (4) 7 14 (4) 16 17 (3) 20
Most commonb
Oral pruritus 4 (4) 4 14 (12) 15 23 (18) 31 27 (20) 31 64 (17) 77 68 (14) 81
Throat irritation 1 (<1) 1 3 (3) 3 5 (4) 5 8 (6) 10 16 (4) 18 17 (3) 19
Ear pruritus 2 (2) 2 5 (4) 7 8 (6) 9 15 (4) 18 15 (3) 18
Mouth edema 3 (3) 3 3 (2) 3 11 (8) 12 17 (4) 18 17 (3) 18
Paresthesia oral 1 (<1) 1 2 (2) 2 4 (3) 5 7 (5) 10 13 (3) 7 14 (3) 18
Mucosal edema 6 (5) 6 3 (2) 3 9 (2) 9 9 (2) 9
Pharyngolaryngeal pain 2 (2) 2 3 (3) 4 2 (2) 3 7 (5) 9 12 (83) 16 14 (3) 18
Bronchitis 3 (3) 6 4 (3) 7 6 (5) 8 1 (<1) 1 11 (3) 16 14 (3) 22
Pharyngitis 3 (3) 3 10 (9) 12 8 (6) 9 1 (<1) 1 19 (5) 22 22 (4) 25
Asthma 5 (5) 6 6 (5) 7 12 (9) 17 12 (9) 19 30 (8) 43 35 (7) 49
Upper respiratory tract infection 9 (8) 11 9 (8) 12 7 (5) 8 9 (7) 9 25 (7) 29 34 (7) 40
Abbreviation: AEs, adverse events.
aData are presented as number of subjects (percentage in treatment group with the event) and number of events (E).
bReported by at least 5% of subjects in any of the active treatment groups.
H. Mosbech et al. / Ann Allergy Asthma Immunol 114 (2015) 134e140 139to impaired quality of life.4 The present data suggest that quality of
life was ameliorated by 1 year of treatment with 6 SQ-HDM
compared with placebo.
Whether improved control of AR contributes to improved control
of coexisting AA has been discussed.26 Acknowledging that AR and
AA represent opposite ends of the same inﬂammatory disease con-
tinuum, guidelines recommend that treatment strategies target AA
and AR.27 The present data combined with data presented in the
publication of the primary results suggest that the SQ HDM SLIT-
tablet has a beneﬁcial effect on HDM AR and AA within the same
population.
An interesting observation from the dataset is that a statistically
signiﬁcantly larger proportion of subjects with a TCRS ¼ 0 during
baseline used a daily ICS dose > 400 mg budesonide at baseline
compared with subjects using an ICS dose 400 mg at baseline (23%
and 16%, respectively). The data suggest that in this trial subjectswith
a daily ICS use > 400 mg budesonide were less likely to report prob-
lems from their diagnosed HDM AR than those who took a daily ICS
dose 400mgbudesonide. Thisﬁndinghas led to anupper limitof ICS
use in a subsequent phase III trial with the SQHDMSLIT-tablet that is
designed to conﬁrm the efﬁcacy of the SQ HDM SLIT-tablet in a pop-
ulation with more severe rhinitis (EudraCT, no 2011-002277-38).
As for the entire trial population, most AEs observed in the trial
were mild local allergic reactions that resolved spontaneously after a
few weeks or months. The most frequent AE in this trial was oral
pruritus; this is a mild local reaction that is common and expected
with SLIT-tablets, because the oral mucosa is directly exposed to the
allergen. Several asthma-related AEs were reported, especially in the
ICS adjustment periods. A certain increase in asthma symptomsduring
these periods was to be expected to determine the lowest level of ICS
necessary to control asthma. There were no indications of any change
in frequency after initiation of treatment. Neither severe systemic
allergic reactions nor any other life-threatening reactions were re-
ported. Thus, the safety proﬁle of the SQ HDM SLIT-tablet in the doses
applied in this trial was substantially more benign than that usually
observed for subcutaneously administered immunotherapy. A moredetailed description of the overall safety data is found in the primary
publication.3
The observed safety proﬁle warrants investigation of a higher
dose, which also might lead to a greater difference between active
treatment and placebo. Previously, doses up to 32 SQ-HDM have
been investigated in phase I, and a dose of 16 SQ-HDMwas found to
be the highest tolerable dose in the short term but with a tolera-
bility proﬁle that could impair compliance in a setting of daily use
over a period of several years.9
The mean symptom and medication scores in the subgroup of
subjects with a TCRS > 0 suggest that the disease level was mild.
Nonetheless, a statistically signiﬁcant effect was found in the highest
dose group, and, hypothetically, subjectswithmore severe symptoms
and considerable room for improvement might beneﬁt to a greater
degree from treatmentwith the SQHDM SLIT-tablet. Themild nature
of AR symptoms in the trial population can be explained by the
circumstance that the primary objective of the trial was to evaluate
the effect of the SQ HDM SLIT-tablet on asthma. The requirement for
concomitantHDMARwas included to increase the likelihood that the
asthmaof the enrolled subjectswas related to HDM. For this reason, a
clinical history of HDMARwas sufﬁcient as an inclusion criterion, but
with no quantitative requirements to the presence of symptoms or
medication use at the time of enrollment. The mild level of AR
became evident during the assessment of symptoms andmedication
scores during the 4-week baseline period. A considerable proportion
of subjects (110 [18%] of entire trial population) were included in the
trial based on a positive history of AR, but in fact had no symptoms or
medication use (TCRS ¼ 0) during the entire 4-week baseline period
and therefore no room for improvement. This could explain why the
prespeciﬁed end points for the evaluation of the efﬁcacy of the SQ
HDM SLIT-tablet in rhinoconjunctivitis did not show a statistically
signiﬁcant difference between active treatment and placebo. Another
limitation to the present efﬁcacy results is the fact that it is a post hoc
subgroup analysis. Future trials should include subjects with clear
evidence of AR, more severe symptoms, and need for medication use
at inclusion. Furthermore, an additional higher dose (12 SQ-HDM)
H. Mosbech et al. / Ann Allergy Asthma Immunol 114 (2015) 134e140140has been included in an ongoing phase III trial with the SQHDMSLIT-
tablet, because the focus remains on the aspect of optimized risk and
beneﬁt.
As reported previously,3 the analysis of the primary end point
in this trial showed that the SQ HDM SLIT-tablet signiﬁcantly
reduced the use of ICS in AA compared with placebo. Taken
together, the 2 publications contribute to the proof of concept for
the treatment of underlying HDM respiratory allergic disease with
the SQ HDM SLIT-tablet, regardless of the dominant manifestation.
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Prespeciﬁed Extrapulmonary Assessments, End Points, Statistics, and
Conclusion
Daily rhinoconjunctivitis symptom and medication scores
Six rhinoconjunctivitis symptoms (4 nose symptoms and 2 eye
symptoms) were assessed on a scale from 0 to 3 (no symptoms to
severe symptoms).
The total daily rhinoconjunctivitis symptom score was calculated
for each patient as the sum of all individual symptom scores. Thus,
the maximum total daily rhinoconjunctivitis symptom score was 18.
The total daily rhinoconjunctivitis medication score is the sum
of the total daily scores for each medication. The individual total
daily medication score was calculated as the unit score multiplied
by the number of units entered in the daily diary by the patient. The
maximum daily rhinoconjunctivitis medication score was 30.
For each patient, the average total daily rhinoconjunctivitis
symptom score and the average total daily rhinoconjunctivitis
medication score (average rhinoconjunctivitis symptom and
medication scores) were calculated
 during the pretreatment ICS tapering period (from visit 2 to 4
weeks before visit 3)
 during the pretreatment ICS stable period (baseline period, the
last 4 weeks before visit 4)
 during the end-of-treatment ICS tapering period (from visit 10 to
4 weeks before visit 12, ie, end-of-trial visit)
 during the end-of-treatment ICS stable period (the last 4 weeks
before visit 12, ie, end-of-trial visit)Statistics. The total daily rhinoconjunctivitis symptom and medi-
cation scores were averaged over the end-of-treatment ICS stable
period (the last 4 weeks before visit 12, ie, end-of-trial visit) for
each patient and analyzed similarly to the primary end point by aeTable 1
ICS use and its relation to the total combined rhinitis score




ICS  400 mg 57 (16%) 308 (4%)
ICS > 400 mg but 800 mg 53 (23%) 181 (77%)
Abbreviations: TCRS, total combined rhinitis score; ICS, inhaled corticosteroid
(budesonide).
The proportion of subjects scoring TCRS ¼ 0 at baseline was higher for subjects with
a daily ICS dose above 400 mg budesonide at baseline than for subjects with ICS at or
below 400 mg budesonide at baseline, namely 23% vs. 16%. In other words, subjects
were more likely to score zero (i.e., experience no problems from their house dust
mite allergic rhinitis) if their daily ICS dose was above 400 mg than if it was below
400 mg. This difference was statistically signiﬁcant (P ¼ .0301).linear mixed model using data from all treatment groups. The
model included treatment group and average score during the
pretreatment ICS stable period (baseline) as ﬁxed effects and
center as a random effect. Two-sided 95% conﬁdence intervals for
the adjusted mean differences and corresponding P values are
presented. These were deﬁned in the statistical analysis plan.The RQLQ(S)
The RQLQ(S) consists of 28 items (questions) in 7 domains, with
each scored on a 7-point scale (0, no impairment; 6, maximum
impairment). Patients were to respond to each question after
recalling their experience during the past week. The 7 domains
are activities, sleep, non-nose and non-eye symptoms, practical
problems, nasal symptoms, eye symptoms, and emotional.
Statistics. Overall scores and domain scores were calculated for
each patient at randomization and initiation of treatment (visit 4,
baseline) and at visit 12 (end-of-trial visit). The change from
baseline to the end of the trial also was calculated for each patient.
Overall and domain scores at visit 12 (end-of-trial visit) were
analyzed similarly to the primary end point with a linear mixed
model including treatment group and baseline value as ﬁxed effects
and center as a random effect.Conclusion of prespeciﬁed extrapulmonary end points
A statistically signiﬁcant difference between the 6-development
units group and placebo was observed for the overall RQLQ(S) score
(P ¼ .0164). This difference was driven primarily by the sleep
domain and the non-nose and non-eye symptoms domain (fatigue,
thirst, decreased productivity, tiredness, poor concentration,
headache, and weariness).
No difference between active treatment and placebo was
detected by rhinoconjunctivitis symptom and medication scores or
for the conjunctival provocation test or skin prick test results.
